Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2026, 2033 and 2053
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Invacare chapter 11 filing
We are advising Highbridge Capital in connection with the restructuring
Integer Holdings $500 million convertible senior notes offering
The 2.125% convertible notes are due 2028
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
Tricida chapter 11 liquidation
We are advising noteholders in connection with Tricida’s chapter 11 proceedings
Sun Pharmaceutical acquisition of Concert Pharmaceuticals
We advised Sun Pharmaceutical on the transaction